In this study, we used data collected as part of a large population-based case-control study of sporadic colon cancer to evaluate associations between dietary intake and Ki- ras mutations. Because we ...

Single-cell analyses of a spontaneous glioblastoma mouse model and tumor-free subventricular zone tissues from patients identify precancerous cells, arising via an oligodendrocyte progenitor lineage, ...

Abstract. The integration of artificial intelligence (AI) in cancer research has significantly advanced radiology, pathology, and multimodal approaches, offering unprecedented capabilities in image ...

CTSMamba is a multitask deep learning model trained on longitudinal CT images of neoadjuvant chemotherapy-treated locally advanced gastric cancer that accurately predicts lymph node metastasis and ...

Abstract. Histotripsy-focused ultrasound treatment gives rise to systemic antitumor immune responses. We investigated whether histotripsy effects on immunosuppressive tumor hypoxia were a potential ...

Abstract. Understanding the vast noncoding cancer genome requires cutting-edge, high-resolution, and accessible strategies. Artificial intelligence is revolutionizing cancer research, enabling ...

Abstract. Radiomics, the extraction of quantitative data from images, holds promise for noninvasively characterizing tumor phenotypes. Tools like LIFEx have improved the accessibility, transparency, ...

The authors show that a subset of ATL cells and HTLV-1–infected T cells express DC–associated molecules. This transition to DC-like T cells evokes immune responses to viral antigens and is associated ...

In gastric cancer, PD-1/PD-L1 blockade success depends on the level of expression of the immune checkpoints. This study reports that METTL3 mediates m6A modification of PD-L1 and that inhibition of ...

Chronic stress facilitates lung cancer immune evasion by inducing M2-like macrophage polarization, supporting the potential of combination therapies targeting both tumor cells and the immune ...

The FDA today granted accelerated approval to linvoseltamab (Lynozyfic, Regeneron) for adults with relapsed or refractory multiple myeloma who have already received at least four therapeutic regimens.